The global Hereditary Angioedema Treatment market to gain from increasing incidences of genetic mutation. Recently Fortune Business Insights, published a report titled, “Hereditary Angioedema Treatment Market Size, Share and Global Trend by Drug Class (C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors), Application (Prophylaxis, Treatment), Route of Administration (IV, Subcutaneous), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) and Geography Forecast till 2025.” As per the report, the global hereditary angioedema treatment market was worth US$ 1883.1 Mn in 2017. The global market is anticipated to expand at a CAGR of 16.8% and reach US$ 6533.3 Mn by the end of 2025. The report classifies the global hereditary angioedema treatment market in various segments and offer a comprehensive overview.
Highlights of the Report:
- In-depth analysis of various insights, namely, Market trends, growth drivers, opportunities, and other related challenges.
- Comprehensive details of key market players, their core competencies, and Market share.
- The potency of suppliers and buyers to make better business decisions.
- Lists out the market size in terms of volume.
Request a Sample Copy of Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/hereditary-angioedema-treatment-market-100164
Key Players Operating in The Market Include:
Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:
- BIOCRYST PHARMACEUTICALS INC.
- Ionis Pharmaceuticals Inc.
- Attune Pharmaceuticals
- Arrowhead Pharmaceuticals Inc.
For more information in the analysis of this report, visit: https://www.globenewswire.com/news-release/2019/07/08/1879378/0/en/Hereditary-Angioedema-Treatment-Market-to-Reach-US-6533-3-Mn-by-2025-Improving-Healthcare-Infrastructure-to-Boost-Market-says-Fortune-Business-Insights.html
C-1 Esterase Inhibitor Segment to Dominate Global Market During Forecast Period
In terms of drug class, the C-1 esterase inhibitor is the most popular drug and dominated the global market in 2017. The segment accounted for 61.3% of the global market in 2017. The trend is unlikely to change during the forecast period 2018-2025 owing to the drug’s reliability among patients and practitioners.
Increasing awareness about the disorder and rising prevalence of the hereditary angioedema are some factors expected to drive the global market during the forecast period. Additionally, technological developments in the hereditary angioedema treatment devices and equipment is expected to boost the global market.
Shire, CSL Behring, and Pharming Group NV to Lead the Global Market
The global market is witnessing entry of new players in the market. However, at present Pharming Group NV, Shire, and CSL Behring are together leading the global market owing to the organization’s strong distribution network. Some of the other companies operating in the global market are BIOCRYST PHARMACEUTICALS INC., Ionis Pharmaceuticals Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals Inc., and Adverum.
More Trending Topics from Fortune Business Insights: